"I just disagree on US listing..."
I'm also dubious about the US listing now that it looks like it will be done at a discount for brokers' clients rather than at a premium and with a serious industry cornerstone investor.
Craig gave a list of reasons, but I guess the main idea is that our direct competitors are in the US and they are valued in many billions. So US investors would be able to directly compare our new apple with their well-known apples and rerate the company accordingly. But making profits would rerate the company equally well.
Regarding your question on profitability there will be 4 major revenue streams in the next year (if FDA fully approves the Pulse):
What do you think that will be worth in the first year in the American market, given that our tech is the gold standard, proven over 20 years, and the competitors are making 100's of millions? After that, there will be more products and we will be expanding globally.
- Clinical trials
- Medical practitioner subscriptions
- OTC sales
- OTC subscriptions
Add to My Watchlist
What is My Watchlist?
